RANI THERAPEUTICS HOLDINGS-A (RANI)

Company Profile

Rani Therapeutics Holdings, Inc. engages in the operation of a clinical stage bio-therapeutics company. The company is headquartered in San Jose, California and currently employs 163 full-time employees. The company went IPO on 2021-07-30. The firm is focused on advancing technologies to enable the administration of biologics and drugs orally, to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The firm has developed a drug-agnostic oral delivery platform, the RaniPill capsule, which is designed to deliver a variety of drug substances, including large molecules, such as peptides, proteins, and antibodies. The RaniPill capsule, the RaniPill GO, is designed to deliver up to a three micrograms (mg) dose of drug with high bioavailability. The capsule includes a coating designed to withstand stomach acid but dissolve in the jejunum portion of the small intestine. Its pipeline includes RT-101, RT-102, RT-105, RT-110 and RT-111. Its RT-101 is an Octreotide for the treatment of NETs and acromegaly. The company manufactures and assembles RaniPill capsules at its facility in San Jose, California.

Company Info

RANI THERAPEUTICS HOLDINGS-A

2051 Ringwood Avenue

San Jose CALIFORNIA

P: 14084573700

CEO: Talat Imran

Employees: 163

Website: https://www.ranitherapeutics.com/